NCT05556473CompletedPhase 1
F-Tryptophan PET/CT in Human Cancers
A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 22 Sept 2022
- Start date
- 29 Sept 2022
- Primary completion date
- 18 Jul 2025
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Diseases
- Neuroendocrine tumours, Colorectal cancer
- NCT number
- NCT05556473
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- From 29 Sept 2022 to the primary completion date, 18 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Tumor surgery or radiation within 1 month prior to the PET scan
- Tumor-directed therapy within 3 months to the area of planned imaging.
- Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).
- Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.
- -Recent (within 1 month) tumor resection or radio-chemotherapy (acute/subacute post-treatment inflammatory changes may cause false positive increases on PET).
Other illness
- -Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.
Other
- Patients who are pregnant or lactating are excluded.
- Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
Who the study is looking for
- Age ≥18 years.
- Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
- Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
- Women of childbearing potential must not be pregnant or breastfeeding.
- Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
- Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
- \- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.
- Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
- ECOG performance status of 2 or better.
- Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \[LAR\], depot) for \>3 months before enrollment may be enrolled on the study, but such treatment is not required.
- Clinical and radiological diagnosis of a breast cancer
- ECOG performance status of 2 or better.
- Histologically confirmed colorectal cancer, which is located in the rectum.
- ECOG performance status of 2 or better.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karmanos Cancer Institute Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.